Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.

Journal Article

Full Text

Duke Authors

Cited Authors

  • Powles, T; Choueiri, TK; Motzer, RJ; Jonasch, E; Pal, S; Tannir, NM; Signoretti, S; Kaldate, R; Scheffold, C; Wang, E; Aftab, DT; Escudier, B; George, DJ

Published Date

  • September 15, 2021

Published In

Volume / Issue

  • 21 / 1

Start / End Page

  • 1023 -

PubMed ID

  • 34525968

Pubmed Central ID

  • PMC8442414

Electronic International Standard Serial Number (EISSN)

  • 1471-2407

Digital Object Identifier (DOI)

  • 10.1186/s12885-021-08693-9

Language

  • eng

Conference Location

  • England